Non-genomic action of beclomethasone dipropionate on bronchoconstriction caused by leukotriene C4 in precision cut lung slices in the horse.
Authors: Fugazzola Maria, Barton Ann-Kristin, Niedorf Frank, Kietzmann Manfred, Ohnesorge Bernhard
Journal: BMC veterinary research
Summary
# Editorial Summary Recurrent airway obstruction (RAO) in horses responds well to glucocorticoid therapy, whether given systemically or via inhalation, yet the precise mechanisms underlying this therapeutic effect remain poorly understood, particularly regarding non-genomic pathways that may operate independently of classical steroid receptor signalling. Fugazzola and colleagues used precision-cut lung slices (PCLS) derived from 13 horses to investigate how beclomethasone dipropionate directly suppresses bronchoconstriction induced by leukotriene C4 (LTC4), a key inflammatory mediator implicated in RAO pathogenesis. The research demonstrated that beclomethasone exerts a significant inhibitory effect on LTC4-induced airway constriction in viable equine lung tissue, suggesting that glucocorticoid action in RAO involves non-genomic mechanisms that operate rapidly on bronchial smooth muscle, independent of the delayed gene transcription pathways traditionally attributed to steroid therapy. These findings have important implications for understanding why inhaled corticosteroids can provide rapid symptomatic relief in horses with RAO, and they suggest that treatment efficacy may depend on both rapid local effects on bronchial tissue and longer-term anti-inflammatory gene regulation. For practitioners, this work underscores the rationale for local (inhalative) administration of glucocorticoids in managing RAO, where direct contact with airway tissue can exploit these immediate pharmacological effects whilst minimising systemic exposure.
Read the full abstract on PubMed
Practical Takeaways
- •Beclomethasone's effectiveness in treating RAO may involve rapid non-genomic mechanisms in addition to traditional genomic pathways, potentially explaining clinical benefits seen with both systemic and inhaled administration
- •The rapid action of glucocorticoids on airway constriction demonstrated in this model suggests they may provide quick relief during acute bronchoconstriction episodes in RAO-affected horses
- •Understanding multiple mechanisms of steroid action could help optimize RAO therapy timing and dosing strategies in clinical practice
Key Findings
- •Beclomethasone dipropionate inhibited leukotriene C4-induced bronchoconstriction in precision-cut lung slices from horses
- •The anti-bronchoconstriction effect of beclomethasone occurred through non-genomic mechanisms independent of classical glucocorticoid receptor pathways
- •Viable equine lung tissue ex-vivo models effectively demonstrated glucocorticoid anti-inflammatory effects on airway smooth muscle contraction